Kyverna Therapeutics, Inc. Common Stock

Stock Chart, Company Information, and Scan Results

$3.47(as of Aug 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Kyverna Therapeutics, Inc. Common Stock Company Information, Fundamentals, and Technical Indicators

Stock Price$3.47
Ticker SymbolKYTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees119
CountyUSA
Market Cap$130.5M

Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. The company's lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis. It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Kyverna Therapeutics, Inc. Common Stock In Our Stock Scanner

As of Aug 14, 2025
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.